Shiseido has signed a binding agreement to sell its Chinese subsidiary, Shiseido Liyuan Cosmetics (SLC), to an investor consortium led by Hong Kong-based private equity firm IDG Capital. SLC makes and sells the Aupres brand in China. The financial terms were not disclosed.
The deal is expected to close between the fourth quarter of 2026 and the first quarter of 2027, subject to regulatory approvals, including in China. Under the transaction, funds managed by IDG Capital will take 95% of the equity through two special purpose vehicles, while a limited partnership enterprise set up mainly by SLC’s new management team will hold the remaining 5%. The deal includes SLC’s Beijing factory and production equipment.
Strategy and China focus
Shiseido frames the sale as part of its push to improve profitability and capital efficiency under its 2030 Medium-Term Strategy. The company says it wants to drive sustainable growth and strengthen its competitiveness in China by concentrating management resources on areas where it “enjoys the greatest competitive advantage.” According to Shiseido, the divestment sheds a business that needs continued investment in product innovation and digital capabilities, allowing the group to focus on priority brands and higher-growth opportunities. Shiseido describes China as a strategically important and attractive, dynamic market where e-commerce is expanding rapidly, consumer behavior is changing and diverse participants are emerging.
Background and transition
SLC was established in 1991 as a joint venture with Beijing Liyuan, a subsidiary of Yiqing Group owned by the Beijing Municipal Government. It has sold the C-beauty brand Aupres since 1994. With the current joint venture agreement set to expire in December 2026, the parties agreed not to renew it. Instead, on September 1, 2026, Shiseido acquired Beijing Liyuan’s 35% stake, giving it full ownership ahead of the sale.
To support a smooth handover, Shiseido will license the intellectual property rights IDG needs to run the business. For a specified period after the transfer, Shiseido will also provide support on new product development, technical assistance for the stable supply of existing products, and continued supply of raw materials and selected products. The company says the remaining collaboration is intended to maintain SLC’s innovation capabilities, product quality and business continuity.
Profit recovery backdrop
The divestment comes days after Shiseido reported a 124.3% jump in core operating profit for Q3 2026, to ¥67.5 billion (US$422.13 million). The company attributed the recovery to restructuring, cost cuts and improved margins rather than strong product demand; like-for-like sales grew 0.7%. Shiseido raised its full-year core operating profit forecast from ¥59 billion (US$433 million) to ¥87 billion (US$546 million).
